SmartTRAK reports that with new products providing a strong tailwind in Q318, the SCS market saw another quarter of strong double-digit growth in both the US and WW, positioning the market for another record year.
SmartTRAK identifies trends to watch in spinal cord stimulation
With the start of a new year, it's time to look back at 2018 and identify continuing and emerging trends in the market for Spinal Cord Stimulation (SCS) that are likely to shape the landscape in 2019 and beyond.
So what’s on the horizon? Anne Staylor, SmartTRAK Managing Editor, gives her predictions for the top technology and market trends to watch.
Among the many interesting and informative topics covered in the article are:
Matt Thomas, General Manager and Vice President of Medtronic’s STIM & Early Intervention business discusses the Company’s growth strategies, plans for innovation, and what’s next in spinal cord stimulation in a podcast interview with SmartTRAK at the American Society of Interventional Pain Physicians (ASIPP) 2018 held March 15-17, 2018 in Orlando, FL
Click the Podcast Link to hear the interview, recorded live at ASIPP 2018. (18:55 minutes.)
To receive a downloadable transcript, click the button below...
Among the many topics covered in the full Q118 SCS Market Recap are:
In May 2017, Nevro CEO Rami Elghandour chatted with Anne Staylor, BioMedGPS Managing Editor/Neuro Analyst to discuss dynamics in the global spinal cord stimulation (SCS) market, including trends, drivers, challenges, competition, and opportunity that would influence the Company’s growth.
A fascinating read then, that now has us appraising a year later if Elghandour's expansion predictions came to pass. Is Nevro still the one to beat as the top leader in the neuromodulation field?
Medtronic’s Stacey Pugh discusses the Company’s new Riptide Aspiration System, new products in development, and growth strategies for the neurovascular business in a podcast interview with SmartTRAK at the International Stroke Conference (ISC) 2018 held Jan. 24-26, 2018 in Los Angeles, CA.
Anne Staylor here with BioMedGPS. We're at the International Stroke Conference in Los Angeles, and today I'm talking with Stacey Pugh of Medtronic Neurovascular. Hi Stacey, thanks for joining me.
In the market for stroke devices, Europe seems to be the proving ground for next generation devices, and several companies with novel technologies are emerging from Europe that could potentially reach the US market in the next several years. One European company taking aim at the US market is Bochum, Germany-based phenox GmbH.
The US Spinal Cord Stimulation market reached new heights in Q417/FY17, driven by new products, expanding indications, and a growing demand for non-narcotic alternatives for treating chronic intractable pain.SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 US Spinal Cord Stimulation Market Recap and Financial Dashboard.
Among the many topics covered in the Q417/FY17 Spinal Cord Stimulation Market Recap are:
Kas Amirdelfan, MD talked with SmartTRAK at the ASRA 2017 Annual Meeting regarding preliminary 12 month results from the SENZA-ULN study
Kas Amirdelfan, MD, principle investigator of the SENZA-Upper Limb and Neck (ULN) study, spoke with SmartTRAK's Anne Staylor at the recent American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting in Lake Buena Vista, FL regarding preliminary 12 month results from SENZA-ULN, the unmet clinical need for chronic intractable ULN pain, factors affecting physician adoption for this indication and what’s next for this research. (See ASRA Poster 4194.)
A transcript of SmartTRAK’s interview with Dr. Amirdelfan is below or click on the following video to view the interview recorded live at ASRA 2017. (13:23 minutes.)
SmartTRAK is excited to be attending NANS 2018 - the North American Neuromodulation Society's 21st Annual Meeting meeting on Jan 11-14, 2018 at Caesars Palace in Las Vegas, Nevada.